Context Therapeutics is trading at $0.41, down 11.15%, after opening-session weakness on August 25, 2026, with no specific cause confirmed.
- No new company-specific announcement or overnight catalyst has been confirmed; the latest major release was its August 5 second-quarter update.
- Biotech and major U.S. indexes are higher, so sector or global sentiment does not explain the decline.
- Continue monitoring for delayed news or filing activity.